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Editorial Comment 
Coronary Stent Occlusion: 
Thrombus Horribilis* 
JOHN A. BITTL, MD, FACC 
Boston, Massachusetts 
Coronary stenting has revolutionized the practice of interven- 
tional cardiology. Coronary stenting has rapidly evolved and 
supplanted other interventional approaches because of its 
excellent angiographic results and low rates of clinical and 
angiographic restenosis. When two randomized trials (1,2) 
showed that stenting could reduce restenosis by 30% com- 
pared with balloon angioplasty inpatients with primary lesions 
in large native coronary arteries, it was anticipated that stents 
would be used for this indication in -10% of patients under- 
going angioplasty. After several studies howed that coronary 
stenting could be used to treat abrupt vessel closure during 
balloon angioplasty (3), stenting was rapidly incorporated in
interventional cardiology to reduce the need for emergency 
bypass urgery. 
Coronary stenting, however, has not been restricted to the 
prevention of native-vessel restenosis or the treatment of 
abrupt vessel closure. Coronary stenting is widely used to treat 
complex lesions previously deemed to be too high risk for 
conventional balloon angioplasty (4,5), as "off-label" treatment 
for complex or saphenous vein grafts lesions (6) not formally 
approved by the Food and Drug Administration and as a 
means to treat minor dissections or residual stenoses during 
conventional angioplasty that were previously regarded as 
borderline but now judged to be suboptimal by current stan- 
dards. It is estimated that >300,000 of the 884,000 interven- 
tional procedures performed worldwide during 1995 involved 
the use of coronary stents (7). 
Subacute thrombosis. Unfortunately, coronary stenting is 
associated with a unique and sobering complication. Sudden 
and complete occlusion of the stent occurs in -4% of patients 
within 2 days to 4 weeks after implantation (8,9). Occlusion of 
stents differs strikingly in timing and severity from abrupt 
vessel closure after conventional balloon angioplasty. Com- 
plete vessel closure after angioplasty also occurs in -4% of 
patients but peaks in incidence while the patient is still in the 
cardiac catheterization laboratory, where the problem can be 
recognized and treated, and causes major ischemic omplica- 
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tions in about one third of patients who experience it (10). In 
contrast, stent occlusion rarely occurs acutely in the laboratory 
(in probably < 1% of patients [9]), but appears ubacutely from 
2 days to 4 weeks after the procedure (8,9) and may appear 
after hospital discharge. Despite the common appellation 
"subacute," early stent occlusion is rarely subtle and causes a 
myocardial infarction or death in the majority of patients who 
experience it (1,2). 
Present study. To characterize the clinical profile of stent 
occlusion, Hasdai et al. (8), in this issue of the Journal, 
examined the records of 761 patients who were treated with a 
wide variety of metallic oronary stents at the Mayo Clinic and 
found that 29 patients (3.8%) experienced this problem. Early 
stent occlusion was associated with death in 5 patients (17%) 
and acute myocardial infarction in 26 (90%) despite the best 
efforts to treat the problem with angioplasty or urokinase. 
Pathogenesis of stent thrombosis. What was the cause of 
stent occlusion in these patients? The bare stainless-steel 
surface within the coronary artery, in conjunction with endo- 
thelial denudation and shear rates outside the normal range 
that arise from incomplete stent deployment or marginal 
dissections, leads to the activation of platelets and exposure of 
the platelet glycoprotein lib/Ilia receptors for fibrinogen 
cross-linking and platelet aggregation (11). Once thrombus has 
formed within a stent, this is a rich source of platelet factor 4, 
which potently blocks the action of the heparin-antithrombin 
III complex (12). Fibrinolytic agents are likely to be ineffective 
for stent thrombosis because these agents activate platelets 
(13) and increase the likelihood of ischemic complications in
unstable angina (14,15), a condition whose pathogenesis shares 
with stent thrombosis the common feature of platelet-rich 
thrombi. Thus, the intense thrombogenicity of clot-bound 
thrombin within the stent, protected from the action of heparin 
and yet capable of activating platelets and converting fibrino- 
gen to fibrin, sustains an occlusion that is resistant to treatment 
with catheter-based approaches or fibrinolytic therapy. 
Like abrupt closure after balloon angioplasty, stent hrom- 
bosis has been observed more frequently in certain clinical and 
angiographic ircumstances. The investigators at the Mayo 
Clinic (8) observed that prior myocardial infarction was more 
common in patients who experienced stent hrombosis than in 
those who did not (79% vs. 53%). The combination of 
preexisting thrombus, poor distal flow from microvascular 
dysfunction and decreased metabolic requirements in the 
infarct zone may increase stasis in the stented segment and the 
risk of stent thrombosis. Other studies have attempted to 
identify risk factors for stent occlusion. Sutton et al. (16) 
observed that the use of stents on an emergency basis or in the 
presence of preexisting thrombus increased the likelihood of 
clinical events within 90 days of stent implantation. 
Prevention. Because stent hrombosis has no good therapy 
and almost always causes severe complications, prevention 
should be the primary goal. Several refinements involving 
technical and antithrombotic advances have been reported to 
reduce the likelihood of stent thrombosis. Colombo (17) has 
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emphasized the need to post-dilate stents with high pressure 
balloons to achieve complete stent expansion. This strategy 
was initially revealed and substantiated byintravascular ultra- 
sound (IVUS) imaging, which frequently showed inadequate 
stent expansion when conventional balloon techniques were 
used for deployment. Now that high pressure balloon inflations 
are routinely used, a polite debate has arisen regarding the 
need for IVUS imaging. Currently, some investigators can 
visualize suboptimal results with IVUS imaging in almost 50% 
of patients undergoing coronary stenting uided by angiogra- 
phy (18-20), whereas others point to a lack of proven clinical 
benefit from IVUS imaging over angiography (21-23). 
Several advances in antithrombotic therapy have also re- 
duced the risk of stent thrombosis. Although warfarin antico- 
agulation was used in patients treated with stents in the 
patients from the Mayo Clinic (8) and in randomized studies 
(1,2) based on the best information available at the time, it may 
not be the optimal antithrombotic therapy to prevent stent 
thrombosis. Recently, Neumann et al. (11) reported that 
activation of platelet fibrinogen receptors, not an elevation in 
plasma fibrinogen or other markers of coagulation, increased 
the risk of stent hrombosis. Sch6mig et al. (24) observed that 
the antiplatelet agent ticlopidine resulted in a lower rate of 
stent thrombosis than anticoagulant therapy in a randomized 
study involving 517 patients (5.4% vs. 0.8%, p = 0.004). In a 
pooled analysis of 2,630 patients treated without anticoagula- 
tion in whom IVUS imaging was rarely used to guide stent 
deployment, Mak et al. (9) reported that only 33 (1.3%) 
developed stent thrombosis. 
Recommendations for avoiding stent thrombosis include 
careful attention to stent deployment technique and anti- 
thrombotic therapy. Residual filling defects within the stent, 
representing fragments of extruded atheromatous plaque or 
small thrombi, should be treated with additional high pressure 
balloon inflations or placement of a short stent. Marginal 
dissections at the proximal inflow or distal outflow of the stent 
should be corrected with additional stents. Patients who re- 
ceive stents in high risk settings, such as acute myocardial 
infarction, abrupt closure or preexisting thrombus, should be 
considered for intensive antithrombotic therapy with pro- 
longed anticoagulation or platelet receptor IIb/IIIa blockers 
(25). Although ticlopidine is superior to warfarin anticoagula- 
tion therapy and platelet IIb/IIIa receptor blockers uch as the 
monoclonal antibody c7E3 are theoretically appealing as a 
means to prevent stent hrombosis, it must be emphasized that 
no antithrombotic regimen has been identified to prevent 
thrombosis of a suboptimally deployed stent. If a technically 
perfect stent result cannot be obtained, as judged by angiog- 
raphy or IVUS imaging, the ineluctable conclusion is that 
coronary artery bypass surgery should be considered for all 
good surgical candidates to prevent the potentially serious 
complications caused by subacute stent thrombosis. 
New stent designs could have a major impact on the risk of 
stent hrombosis (26). In the Benestent-II Pilot Study involving 
207 consecutive patients (27), the use of an investigational 
heparin-coated stent did not cause documented stent throm- 
bosis in any patient. Although the absence of stent hrombosis 
may be attributed to the heparin coating of the stent, other 
factors associated with a low risk of stent thrombosis in this 
study included the extensive xperience of the team involved in 
placing stents and exclusion of patients with unstable angina, 
myocardial infarction or abrupt vessel closure. Although these 
preliminary results provide a glimmer of hope for reducing 
stent hrombosis, it is difficult to judge whether the results are 
generalizable to the worldwide interventional community im- 
planting stents for a broader range of indications, each of 
which carries a finite risk for stent thrombosis. 
Treatment of stent thrombosis. If stent thrombosis occurs 
despite all efforts to prevent it, the initial treatment should 
follow the approach of Hasdai et al. (8) using immediate 
repeat angioplasty and bypass surgery if needed. It seems 
intuitive, however, that repeat use of the same balloon inflation 
strategy that led to the first episode of stent thrombosis falls 
short of a more definitive strategy required to prevent asecond 
episode. In contrast, repeat inflation with a larger balloon or a 
noncompliant balloon to a higher pressure may reduce the risk 
of recurrent stent thrombosis if the initial episode of stent 
thrombosis can be attributed to underexpansion f the stent. If 
adjunctive antithrombotic therapy is required, the theoretical 
disaggregating action of platelet IIb/IIIa receptor blockers 
makes these agents more appealing than fibrinolytic agents. If 
no correctable cause of stent thrombosis can be identified, 
bypass urgery is indicated. Bypass urgery was used in 9 of 29 
patients with stent thrombosis at the Mayo Clinic (8). 
Conclusions. Coronary stenting is evolving rapidly. Evidence- 
based guidelines for coronary stenting will also change rapidly. 
In the meantime, careful case and vessel selection, optimal 
stent deployment and improved antithrombotic therapy are 
steps toward reducing the incidence of stent occlusion. Better 
studies are urgently needed to define the risk factors and 
optimal treatment for stent thrombosis. In the long term, a 
better understanding of the biology of coronary stents from 
experimental nd clinical studies is needed to eliminate the 
serious problem of stent thrombosis. 
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